Senior adult oncology clinical practice guidelines in oncology

Lodovico Balducci, Harvey Jay Cohen, Paul F. Engstrom, David S Ettinger, Jeffrey Halter, Leo I. Gordon, Krystyna Kiel, Andrew Kneier, Dean Lim, Stephen H. Petersdorf, Ronnie Rosenthal, Rebecca Silliman, Julie M. Vose, Michael J. Walker, Babu Zachariah

Research output: Contribution to journalArticle

Abstract

Because aging is highly individualized, the best guide as to whether cancer treatment is appropriate may be provided by careful assessment of the older patient (see page 574). Screening can be used to identify patients who can benefit from a comprehensive assessment (i.e., CGA). Chronologic age is not reliable in estimating life expectancy, functional reserve, or the risk of treatment complications. Careful assessment, using the criteria described in this NCCN Senior Adult Oncology guideline, allows oncologists to divide older patients into three groups as follows: (1) patients who are functionally independent (i.e., ADL and IADL independent) and without comorbidity and, thus, are candidates for most forms of standard cancer treatment; (2) patients with major functional impairment and/or complex comorbidity (i.e., dependent in one or more ADL with severe comorbidity or advanced geriatric syndromes [such as severe dementia]) who are candidates only for palliative treatment; and (3) patients with intermediate functional impairment (i.e., in between groups 1 and 2) who cannot tolerate life-prolonging curative therapy but who may benefit from some special pharmacological approach (such as reduction in the initial dose of chemotherapy with subsequent dose escalations as tolerated). All three groups of patients are expected to die of cancer or experience complications within their lifetimes (see page 574). A fourth group of patients includes those whose life expectancy is so short that they are unlikely to develop morbidity from cancer; these patients can receive symptom management and supportive care (see NCCN's Supportive Care Guidelines). Elderly patients who are deemed able to tolerate curative treatment have special needs. In general, age is not a primary consideration for surgical risk. However, concurrent radiation therapy/chemotherapy should be used cautiously; dose modification of chemotherapy may be necessary. Chemotherapy can lead to problems (such as neurotoxicity, cardiac toxicity, mucositis) that can be decreased or prevented by using specific recommendations from the NCCN Senior Adult Oncology Guideline (see page 576).

Original languageEnglish (US)
Pages (from-to)572-590
Number of pages19
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume3
Issue number4
StatePublished - Jul 2005

Fingerprint

Medical Oncology
Practice Guidelines
Comorbidity
Drug Therapy
Guidelines
Activities of Daily Living
Life Expectancy
Neoplasms
Therapeutics
Mucositis
Palliative Care
Geriatrics
Dementia
Radiotherapy
Pharmacology
Morbidity

Keywords

  • Carcinoma
  • Chemotherapy
  • Elderly
  • Geriatrics
  • NCCN clinical practice guidelines
  • Supportive care

ASJC Scopus subject areas

  • Oncology

Cite this

Balducci, L., Cohen, H. J., Engstrom, P. F., Ettinger, D. S., Halter, J., Gordon, L. I., ... Zachariah, B. (2005). Senior adult oncology clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 3(4), 572-590.

Senior adult oncology clinical practice guidelines in oncology. / Balducci, Lodovico; Cohen, Harvey Jay; Engstrom, Paul F.; Ettinger, David S; Halter, Jeffrey; Gordon, Leo I.; Kiel, Krystyna; Kneier, Andrew; Lim, Dean; Petersdorf, Stephen H.; Rosenthal, Ronnie; Silliman, Rebecca; Vose, Julie M.; Walker, Michael J.; Zachariah, Babu.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 3, No. 4, 07.2005, p. 572-590.

Research output: Contribution to journalArticle

Balducci, L, Cohen, HJ, Engstrom, PF, Ettinger, DS, Halter, J, Gordon, LI, Kiel, K, Kneier, A, Lim, D, Petersdorf, SH, Rosenthal, R, Silliman, R, Vose, JM, Walker, MJ & Zachariah, B 2005, 'Senior adult oncology clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 3, no. 4, pp. 572-590.
Balducci, Lodovico ; Cohen, Harvey Jay ; Engstrom, Paul F. ; Ettinger, David S ; Halter, Jeffrey ; Gordon, Leo I. ; Kiel, Krystyna ; Kneier, Andrew ; Lim, Dean ; Petersdorf, Stephen H. ; Rosenthal, Ronnie ; Silliman, Rebecca ; Vose, Julie M. ; Walker, Michael J. ; Zachariah, Babu. / Senior adult oncology clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2005 ; Vol. 3, No. 4. pp. 572-590.
@article{32e514b5060e437eb279b8ac3c5912fb,
title = "Senior adult oncology clinical practice guidelines in oncology",
abstract = "Because aging is highly individualized, the best guide as to whether cancer treatment is appropriate may be provided by careful assessment of the older patient (see page 574). Screening can be used to identify patients who can benefit from a comprehensive assessment (i.e., CGA). Chronologic age is not reliable in estimating life expectancy, functional reserve, or the risk of treatment complications. Careful assessment, using the criteria described in this NCCN Senior Adult Oncology guideline, allows oncologists to divide older patients into three groups as follows: (1) patients who are functionally independent (i.e., ADL and IADL independent) and without comorbidity and, thus, are candidates for most forms of standard cancer treatment; (2) patients with major functional impairment and/or complex comorbidity (i.e., dependent in one or more ADL with severe comorbidity or advanced geriatric syndromes [such as severe dementia]) who are candidates only for palliative treatment; and (3) patients with intermediate functional impairment (i.e., in between groups 1 and 2) who cannot tolerate life-prolonging curative therapy but who may benefit from some special pharmacological approach (such as reduction in the initial dose of chemotherapy with subsequent dose escalations as tolerated). All three groups of patients are expected to die of cancer or experience complications within their lifetimes (see page 574). A fourth group of patients includes those whose life expectancy is so short that they are unlikely to develop morbidity from cancer; these patients can receive symptom management and supportive care (see NCCN's Supportive Care Guidelines). Elderly patients who are deemed able to tolerate curative treatment have special needs. In general, age is not a primary consideration for surgical risk. However, concurrent radiation therapy/chemotherapy should be used cautiously; dose modification of chemotherapy may be necessary. Chemotherapy can lead to problems (such as neurotoxicity, cardiac toxicity, mucositis) that can be decreased or prevented by using specific recommendations from the NCCN Senior Adult Oncology Guideline (see page 576).",
keywords = "Carcinoma, Chemotherapy, Elderly, Geriatrics, NCCN clinical practice guidelines, Supportive care",
author = "Lodovico Balducci and Cohen, {Harvey Jay} and Engstrom, {Paul F.} and Ettinger, {David S} and Jeffrey Halter and Gordon, {Leo I.} and Krystyna Kiel and Andrew Kneier and Dean Lim and Petersdorf, {Stephen H.} and Ronnie Rosenthal and Rebecca Silliman and Vose, {Julie M.} and Walker, {Michael J.} and Babu Zachariah",
year = "2005",
month = "7",
language = "English (US)",
volume = "3",
pages = "572--590",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Senior adult oncology clinical practice guidelines in oncology

AU - Balducci, Lodovico

AU - Cohen, Harvey Jay

AU - Engstrom, Paul F.

AU - Ettinger, David S

AU - Halter, Jeffrey

AU - Gordon, Leo I.

AU - Kiel, Krystyna

AU - Kneier, Andrew

AU - Lim, Dean

AU - Petersdorf, Stephen H.

AU - Rosenthal, Ronnie

AU - Silliman, Rebecca

AU - Vose, Julie M.

AU - Walker, Michael J.

AU - Zachariah, Babu

PY - 2005/7

Y1 - 2005/7

N2 - Because aging is highly individualized, the best guide as to whether cancer treatment is appropriate may be provided by careful assessment of the older patient (see page 574). Screening can be used to identify patients who can benefit from a comprehensive assessment (i.e., CGA). Chronologic age is not reliable in estimating life expectancy, functional reserve, or the risk of treatment complications. Careful assessment, using the criteria described in this NCCN Senior Adult Oncology guideline, allows oncologists to divide older patients into three groups as follows: (1) patients who are functionally independent (i.e., ADL and IADL independent) and without comorbidity and, thus, are candidates for most forms of standard cancer treatment; (2) patients with major functional impairment and/or complex comorbidity (i.e., dependent in one or more ADL with severe comorbidity or advanced geriatric syndromes [such as severe dementia]) who are candidates only for palliative treatment; and (3) patients with intermediate functional impairment (i.e., in between groups 1 and 2) who cannot tolerate life-prolonging curative therapy but who may benefit from some special pharmacological approach (such as reduction in the initial dose of chemotherapy with subsequent dose escalations as tolerated). All three groups of patients are expected to die of cancer or experience complications within their lifetimes (see page 574). A fourth group of patients includes those whose life expectancy is so short that they are unlikely to develop morbidity from cancer; these patients can receive symptom management and supportive care (see NCCN's Supportive Care Guidelines). Elderly patients who are deemed able to tolerate curative treatment have special needs. In general, age is not a primary consideration for surgical risk. However, concurrent radiation therapy/chemotherapy should be used cautiously; dose modification of chemotherapy may be necessary. Chemotherapy can lead to problems (such as neurotoxicity, cardiac toxicity, mucositis) that can be decreased or prevented by using specific recommendations from the NCCN Senior Adult Oncology Guideline (see page 576).

AB - Because aging is highly individualized, the best guide as to whether cancer treatment is appropriate may be provided by careful assessment of the older patient (see page 574). Screening can be used to identify patients who can benefit from a comprehensive assessment (i.e., CGA). Chronologic age is not reliable in estimating life expectancy, functional reserve, or the risk of treatment complications. Careful assessment, using the criteria described in this NCCN Senior Adult Oncology guideline, allows oncologists to divide older patients into three groups as follows: (1) patients who are functionally independent (i.e., ADL and IADL independent) and without comorbidity and, thus, are candidates for most forms of standard cancer treatment; (2) patients with major functional impairment and/or complex comorbidity (i.e., dependent in one or more ADL with severe comorbidity or advanced geriatric syndromes [such as severe dementia]) who are candidates only for palliative treatment; and (3) patients with intermediate functional impairment (i.e., in between groups 1 and 2) who cannot tolerate life-prolonging curative therapy but who may benefit from some special pharmacological approach (such as reduction in the initial dose of chemotherapy with subsequent dose escalations as tolerated). All three groups of patients are expected to die of cancer or experience complications within their lifetimes (see page 574). A fourth group of patients includes those whose life expectancy is so short that they are unlikely to develop morbidity from cancer; these patients can receive symptom management and supportive care (see NCCN's Supportive Care Guidelines). Elderly patients who are deemed able to tolerate curative treatment have special needs. In general, age is not a primary consideration for surgical risk. However, concurrent radiation therapy/chemotherapy should be used cautiously; dose modification of chemotherapy may be necessary. Chemotherapy can lead to problems (such as neurotoxicity, cardiac toxicity, mucositis) that can be decreased or prevented by using specific recommendations from the NCCN Senior Adult Oncology Guideline (see page 576).

KW - Carcinoma

KW - Chemotherapy

KW - Elderly

KW - Geriatrics

KW - NCCN clinical practice guidelines

KW - Supportive care

UR - http://www.scopus.com/inward/record.url?scp=27744597661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744597661&partnerID=8YFLogxK

M3 - Article

C2 - 16038647

AN - SCOPUS:27744597661

VL - 3

SP - 572

EP - 590

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 4

ER -